MENU
TRDA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Entrada Therapeutics (TRDA) Ownership - Who owns Entrada Therapeutics?
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible... Show more
Profile
Industry
N/A
Address
One Design Center Place
Phone
+1 857 520-9158
Employees
159
Web
https://www.entradatx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
330.83M
P/E Ratio
5.24
Total Cash
420M
Projected Growth
N/A
Total Debt
59.21M
Revenue
210.78M
Risk (Beta)
-0.13
Dividend Yield
N/A
Total Cash/Share
11.17
Total Debt/Equity
N/A
Revenue/Share
5.40 USD as % of share price
Fundamentals
TRDA
Capitalization
331M
P/E Ratio
5.24
Risk (Beta)
-0.13
Dividend Yield
N/A
Total Cash
420M
Total Cash/Share
11.17
Total Debt
59.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
5.40%
Revenue
211M
ROE
N/A
Book Value
429M
P/B Ratio
0.77
Cash Flow
N/A
Earnings
1.76
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
4K
Current Ratio
11.15
Current Revenue Per Employee
204360.66
Dividends Per Share - Security
N/A
EBITDA
50.8M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
13.18
Shares Held By Institutions
686M
Shares Outstanding - Current
37.6M
Total Liabilities
97.6M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-49.104
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
One Design Center Place
Phone
+1 857 520-9158
Employees
159
Web
https://www.entradatx.com